Latest News
-
Thursday - December 6, 2012
Not intended for U.S. and UK media
Bayer Submits VEGF Trap-Eye (aflibercept) for Treatment of Macular Edema Following Central Retinal Vein Occlusion in EU » more
-
Wednesday - December 5, 2012
Not intended for U.S. and UK Media
Bayer receives green light for new long-term contraceptive in the EU
Company plans to market the new low dose levonorgestrel-releasing intrauterine system under the brand name “Jaydess” / Product provides reliable contraception for up to three years » more
-
Friday - November 30, 2012
Science For A Better Life:
150 years of Bayer: Success through innovation and change
Dekkers: Bayer products have become indispensable to our lives / Numerous events planned in 2013 » more
-
Friday - November 30, 2012
Not intended for U.S. and UK Media: 54th American Society of Hematology (ASH) Annual Meeting and Exposition 2012:
New data on Bayer’s Xarelto® (Rivaroxaban) as a Single-Drug Solution for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
Pooled data from EINSTEIN trials show oral rivaroxaban has an improved benefit-risk profile and lower rates of major bleeding compared with standard therapy / New data also show reduced hospital stay and improved patient-reported satisfaction with rivaroxaban for patients with acute symptomatic PE » more
-
Thursday - November 29, 2012
European Innovative Medicines Initiative (IMI):
Bayer supports pharmaceutical research in Europe
Bayer HealthCare and Leiden University coordinate consortium to optimize binding kinetics for drug candidates » more
-
Wednesday - November 28, 2012
New edition of research, the Bayer Scientific Magazine, published
Improving people’s lives through innovation
Systematic biotechnology: life science research for new therapies and a reliable food supply / Potatoes: head start for young tubers / Catalysis: turbocharged chemistry for innovative molecules » more
-
Wednesday - November 28, 2012
Not intended for U.S. and UK Media - Hemophilia solutions:
Bayer completes recruitment of first cohort for novel recombinant factor VIIa (rFVIIa) protein Phase II/III study
Investigational new treatment for Hemophilia A and Hemophilia B patients who have developed neutralizing antibodies » more
-
Tuesday - November 27, 2012
Not intended for U.S. and UK Media
Bayer receives approval for EYLEA® in Europe for the Treatment of Wet Age-Related Macular Degeneration
New treatment allows dosing every other month following three initial monthly injections in wet AMD patients » more
-
Monday - November 26, 2012
Not intended for UK Media
Bayer HealthCare acquires software developer Radimetrics Inc.
Transaction expands Bayer leadership in medical information technology for integrating and delivering data / Radimetrics software delivers quick, accurate and cost-efficient radiation monitoring and patient management » more
-
Wednesday - November 21, 2012
Merger agreement terminated:
Bayer forgoes proposed acquisition of Schiff Nutrition International
Bayer committed to continue with bolt-on acquisition strategy » more
-
Wednesday - November 21, 2012
Symposium on “New Ways in Weed Control Research”:
“Agriculture worldwide needs new solutions” Scientists call for urgent turnaround in weed-control research
Growing weed resistance in all major production areas of the world / More than 25-year lull in bringing herbicides with new modes of action to market » more
-
Wednesday - November 21, 2012
Special exhibit on futuristic Solar Impulse aircraft:
Aviation pioneer Bertrand Piccard at Bayer in Leverkusen
Fuel-less around-the-world-flight scheduled for 2015 » more
-
Tuesday - November 20, 2012
Not intended for U.S. and UK media
Bayer’s Xarelto® (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism (PE) and the Prevention of Recurrent Deep Vein Thrombosis (DVT) and PE in the EU
Blood clots obstructing blood flow in deep veins or in the lungs kill more than 2,300 people every day worldwide and urgent action is essential to save lives / Rivaroxaban works as fast as injectable enoxaparin, providing efficacy when needed for as long as needed / Rivaroxaban offers the only oral single-drug solution for the treatment of PE and long-term prevention of DVT and PE, without the need for injections or monitoring / Rivaroxaban is approved to protect patients from blood clots across more venous and arterial thromboembolic diseases than any other novel oral anticoagulant » more
-
Wednesday - November 14, 2012
Press Forum
Bayer's Perspective on Innovation 2012 » more
-
Wednesday - November 14, 2012
Innovative wall coating can save lives
Bayer MaterialScience and partners develop efficient and affordable seismic protection
MAPEI takes over global distribution of the system » more
-
Tuesday - November 13, 2012
Not intended for U.S. and UK Media
Landmark Phase III Study of Bayer’s Xarelto® (Rivaroxaban) Initiated for the Secondary Prevention of Myocardial Infarction and Death in Patients with Coronary or Peripheral Artery Disease
20,000-patient study will be conducted in collaboration with Population Health Research Institute / Composite of cardiovascular death, myocardial infarction and stroke as primary efficacy endpoint / Rivaroxaban is the first novel oral anticoagulant under assessment in this high risk patient population » more
-
Monday - November 12, 2012
9th European Diabetes Nursing Symposium
Calling for a partnered approach in diabetes education
Bayer HealthCare honors commitment for raising awareness of blood glucose management » more
-
Monday - November 12, 2012
Bayer MaterialScience participates in the “Working Worlds in 2030” network project
What will a typical work day be like in 20 years?
Students develop creative ideas and concepts for working life of the future » more
-
Friday - November 9, 2012
Young Environmental Leader Award 2012
Bayer and UNEP Honor Three Young Environmentalists from Costa Rica, Kenya and Vietnam » more
-
Wednesday - November 7, 2012
Bayer CropScience at CropWorld 2012:
Cultivating new ideas and answers in Agriculture
One of the strongest pipelines of new products in the industry / Commitment to Sustainable Crop Solutions in Seeds, Small Molecules and Biologics » more
Copyright @ Bayer AG